Home  »  Companies   »  Evoke Pharma Inc. (EVOK) Is Now En Route to Higher...

Evoke Pharma Inc. (EVOK) Is Now En Route to Higher Prices

Evoke Pharma Inc. (NASDAQ: EVOK) is -33.72% lower on its value in year-to-date trading and has touched a low of $1.20 and a high of $6.06 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EVOK stock was last observed hovering at around $1.74 in the last trading session, with the day’s loss setting it -0.03% off its average median price target of $9.00 for the next 12 months. It is also 81.0% off the consensus price target high of $9.00 offered by 1 analysts, but current levels are 81.0% higher than the price target low of $9.00 for the same period.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently trading at $1.71, the stock is -2.76% and -26.77% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.23 million and changing -1.72% at the moment leaves the stock -50.32% off its SMA200. EVOK registered 35.71% gain for a year compared to 6-month loss of -60.78%. The firm has a 50-day simple moving average (SMA 50) of $2.6376 and a 200-day simple moving average (SMA200) of $3.2790.

The stock witnessed a -5.00% gain in the last 1 month and extending the period to 3 months gives it a -36.19%, and is 11.76% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.27% over the week and 7.07% over the month.

Evoke Pharma Inc. (EVOK) has around 5 employees, a market worth around $52.17M and $0.02M in sales. Distance from 52-week low is 42.50% and -71.80% from its 52-week high.

Evoke Pharma Inc. (EVOK) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Evoke Pharma Inc. (EVOK) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Evoke Pharma Inc. is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.06 with sales reaching $830k over the same period.The EPS is expected to shrink by -61.50% this year, but quarterly earnings will post 34,378.30% year-over-year.

Evoke Pharma Inc. (EVOK) Top Institutional Holders

37 institutions hold shares in Evoke Pharma Inc. (EVOK), with 1.03M shares held by insiders accounting for 3.20% while institutional investors hold 19.64% of the company’s shares. The shares outstanding are 32.37M, and float is at 31.38M with Short Float at 3.47%. Institutions hold 19.01% of the Float.

The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 1.03 million shares valued at $2.66 million. The investor’s holdings represent 3.18% of the EVOK Shares outstanding. As of Dec 30, 2020, the second largest holder is Morgan Stanley with 0.5 million shares valued at $1.3 million to account for 1.56% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 0.19 million shares representing 0.58% and valued at over $0.48 million, while Geode Capital Management, LLC holds 0.49% of the shares totaling 0.16 million with a market value of $0.41 million.

Evoke Pharma Inc. (EVOK) Insider Activity

A total of 6 insider transactions have happened at Evoke Pharma Inc. (EVOK) in the last six months, with sales accounting for 4 and purchases happening 2 times. The most recent transaction is an insider sale by Gonyer David A, the company’s President and CEO. SEC filings show that Gonyer David A sold 23,954 shares of the company’s common stock on Dec 14 at a price of $2.94 per share for a total of $70425.0. Following the sale, the insider now owns 0.34 million shares.

Evoke Pharma Inc. disclosed in a document filed with the SEC on Dec 11 that Gonyer David A (President and CEO) sold a total of 48,046 shares of the company’s common stock. The trade occurred on Dec 11 and was made at $2.90 per share for $0.14 million. Following the transaction, the insider now directly holds 0.36 million shares of the EVOK stock.

Still, SEC filings show that on Dec 11, D’Onofrio Matthew J (Exec VP, Chief Bus. Officer) disposed off 40,357 shares at an average price of $2.91 for $0.12 million. The insider now directly holds 283,997 shares of Evoke Pharma Inc. (EVOK).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Evoke Pharma Inc. (EVOK): Who are the competitors?

The company’s main competitors (and peers) include Ironwood Pharmaceuticals Inc. (IRWD) that is trading 10.96% up over the past 12 months. ANI Pharmaceuticals Inc. (ANIP) is -27.95% down on the 1-year trading charts. Short interest in the company’s stock has fallen -42.77% from the last report on Apr 14, 2021 to stand at a total of 1.09 million short shares sold with a short interest ratio of 1.78.

Related Posts




Download Free eBook For

100% free. stop anytime no spam